It’s been quite a week for New Jersey, and for the BioNJ Team. The good news included Bridgewater-based BioNJ Member Helsinn Group and Eisai Inc. receiving Food and Drug Administration (FDA) approval AKYNZEO® and Morris Plains-based BioNJ Member Immunomedics, Inc. announcing that the European Medicines Agency (EMA) has granted orphan drug status for one of the company’s solid-tumor antibody-drug conjugates.
Add to that the fact that on Monday and Tuesday BioNJ’s 2nd Annual CEO Summit TOOK IT to the TOP with 250 participants, and maybe it was more than a pretty good week. Our great thanks to all who contributed to the CEO Summit. Click here to read more.